CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review.

Area of Science:

• Oncology
• Immunotherapy
• Surgical Oncology

Background:

• Chimeric antigen receptor (CAR)-T cell therapy is effective in hematologic malignancies but faces challenges in solid tumors.
• Solid tumors present barriers like heterogeneity, immune suppression, and poor T-cell infiltration, limiting CAR-T efficacy.
• Peripheral solid tumors include melanoma, sarcomas, breast, and head and neck cancers.

Purpose of the Study:

• To review the integration of CAR-T cell therapy with reconstructive oncologic surgery for peripheral solid tumors.
• To explore emerging strategies for enhancing CAR-T cell therapy in solid tumors.
• To evaluate the potential impact of combined CAR-T therapy and surgery on patient outcomes.

Main Methods:

• Review of current literature and clinical studies on CAR-T cell therapy in solid tumors.
• Discussion of advanced CAR-T cell strategies: localized delivery, improved CAR design, and novel antigen targets (HER2, MUC1, GD2, B7-H3).
• Analysis of the synergistic effects of combining CAR-T therapy with surgical interventions.

Main Results:

• Emerging strategies show promise in overcoming solid tumor barriers for CAR-T cell therapy.
• Clinical studies indicate improved local tumor control and optimized surgical resections with combined approaches.
• Integration of CAR-T therapy with surgery may decrease tumor recurrence rates.

Conclusions:

• CAR-T cell therapy is a potential adjunctive treatment in oncologic surgery for solid tumors.
• Combining CAR-T therapy with surgery can positively influence reconstructive outcomes.
• Interdisciplinary collaboration is crucial for improving patient outcomes in solid tumor management.